KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Asset Writedowns and Impairment (2022 - 2026)

Pacific Biosciences Of California has reported Asset Writedowns and Impairment over the past 4 years, most recently at -$200000.0 for Q4 2025.

  • For Q4 2025, Asset Writedowns and Impairment fell 100.11% year-over-year to -$200000.0; the TTM value through Dec 2025 reached $14.8 million, down 94.6%, while the annual FY2025 figure was $9.6 million, 94.81% down from the prior year.
  • Asset Writedowns and Impairment for Q4 2025 was -$200000.0 at Pacific Biosciences Of California, down from $15.0 million in the prior quarter.
  • Over five years, Asset Writedowns and Impairment peaked at $180.8 million in Q4 2024 and troughed at -$200000.0 in Q4 2025.
  • A 4-year average of $23.5 million and a median of $1.4 million in 2022 define the central range for Asset Writedowns and Impairment.
  • On a YoY basis, Asset Writedowns and Impairment climbed as much as 499900.0% in 2025 and fell as far as 100.11% in 2025.
  • Year by year, Asset Writedowns and Impairment stood at $3.4 million in 2022, then soared by 75.39% to $5.9 million in 2023, then skyrocketed by 2967.79% to $180.8 million in 2024, then crashed by 100.11% to -$200000.0 in 2025.
  • Business Quant data shows Asset Writedowns and Impairment for PACB at -$200000.0 in Q4 2025, $15.0 million in Q1 2025, and $180.8 million in Q4 2024.